Base de dados : MEDLINE
Pesquisa : D03.383.606.790 [Categoria DeCS]
Referências encontradas : 418 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 42 ir para página                         

  1 / 418 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745677
[Au] Autor:Pilipovich AA; Golubev VL
[Ad] Endereço:I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
[Ti] Título:[The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
[Ti] Título:Agonist dofaminovykh retseptorov piribedil v terapii bolezni Parkinsona..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(6):83-90, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:In this paper, the authors review the current foreign and domestic literature on a role of the agonist of dopamine receptors piribedil in the treatment of Parkinson's disease. The results of the main studies of the efficacy and safety of piribedil, mechanisms of actions and a comparative characteristics with other dopamine receptors agonist are reviewed.
[Mh] Termos MeSH primário: Antiparkinsonianos/uso terapêutico
Agonistas de Dopamina/uso terapêutico
Doença de Parkinson/tratamento farmacológico
Piribedil/uso terapêutico
[Mh] Termos MeSH secundário: Antiparkinsonianos/farmacologia
Agonistas de Dopamina/farmacologia
Seres Humanos
Atividade Motora/efeitos dos fármacos
Neuroproteção
Piribedil/farmacologia
Receptores Dopaminérgicos/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Dopamine Agonists); 0 (Receptors, Dopamine); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171176183-90


  2 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28665152
[Au] Autor:Çelik B; Özdemir S; Barla Demirkoz A; Üner M
[Ad] Endereço:a Department of Pharmaceutical Technology , Bezmialem Vakif University , Fatih, Istanbul , Turkey.
[Ti] Título:Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson's disease: physical characterization and ex vivo drug permeation through buccal mucosa.
[So] Source:Drug Dev Ind Pharm;43(11):1836-1845, 2017 Nov.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was optimization of buccal piribedil (PR) mucoadhesive tablets to improve its low bioavailability and provide controlled release for the treatment of Parkinson's disease. METHODS: Buccal tablets were prepared by direct compression method using carbomer (CP), carboxymethyl cellulose (CMC), and hydroxypropyl methylcellulose (HPMC) as mucoadhesive polymers. Physical properties of powder mixtures and buccal tablets were evaluated. Physicochemical compatibility between ingredients was investigated with infrared spectroscopy and differential scanning calorimetry analysis. In vitro dissolution profiles and drug release kinetics of buccal tablets were investigated. Mucoadhesion and ex vivo permeation studies were performed using sheep buccal mucosa. RESULTS: Powder mixtures demonstrated sufficient flow properties and physical characteristics of all tablet formulations were within compendia limits. Tablet ingredients were absent of any chemical interactions. CP tablets displayed slower drug release compared to HPMC tablets with zero order release, while CMC tablets lost their integrity and released entire drug after 6 h following Higuchi model. All formulations displayed adequate mucoadhesion and steady state flux of PR through buccal mucosa were higher with HPMC compared to CP-containing tablets. CONCLUSION: Overall, HPMC was found to combine desired controlled release and mucoadhesion characteristics with sufficient pharmaceutical quality for optimization of buccal tablets. Piribedil mucoadhesive buccal tablets designed for the first time may introduce a new alternative for the treatment of Parkinson's disease.
[Mh] Termos MeSH primário: Resinas Acrílicas/química
Varredura Diferencial de Calorimetria/métodos
Derivados da Hipromelose/química
Mucosa Bucal/química
Doença de Parkinson/metabolismo
Doença de Parkinson/fisiopatologia
Piribedil/administração & dosagem
Piribedil/metabolismo
Comprimidos/química
[Mh] Termos MeSH secundário: Adesividade
Administração Bucal
Animais
Química Farmacêutica
Preparações de Ação Retardada
Piribedil/química
Ovinos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acrylic Resins); 0 (Delayed-Action Preparations); 0 (Tablets); 0 (carbomer); 3NXW29V3WO (Hypromellose Derivatives); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1349785


  3 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28399106
[Au] Autor:Zakharov VV; Gromova DO
[Ad] Endereço:Sechenov First Moscow State Medical University, Moscow, Russia.
[Ti] Título:[Current approaches to management of patients with mild cognitive impairment].
[Ti] Título:Sovremennye podkhody k vedeniiu patsientov s umerennymi kognitivnymi narusheniiami..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(3):107-112, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Mild cognitive impairment (MCI) is an intermediate stage between normal aging and dementia. The prevalence of MCI among elderly people is 12-17% but the risk of progression of cognitive impairment and development of dementia during 5 years is up to 70%. Cerebral vascular diseases and initial stages of neurodegenerative processes are the cause of MCI. Clinical characteristics of MCI depend on the main etiological factor. To decrease the severity of symptoms and prevent the progression of cognitive impairment in MCI patients, pharmacotherapy and non-medication methods, including diet optimization, stimulation of mental and physical activity, are used. Dopaminergic and noradrenergic therapy is most prevalent among pharmacological methods.
[Mh] Termos MeSH primário: Transtornos Cerebrovasculares/complicações
Disfunção Cognitiva/terapia
Agonistas de Dopamina/uso terapêutico
Piribedil/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Envelhecimento/fisiologia
Envelhecimento/psicologia
Disfunção Cognitiva/diagnóstico
Disfunção Cognitiva/tratamento farmacológico
Disfunção Cognitiva/etiologia
Demência/etiologia
Dieta
Progressão da Doença
Agonistas de Dopamina/farmacocinética
Exercício
Feminino
Seres Humanos
Masculino
Piribedil/farmacocinética
Prevalência
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dopamine Agonists); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro201711731107-112


  4 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26841263
[Au] Autor:Ross AM; Rahmani S; Prieskorn DM; Dishman AF; Miller JM; Lahann J; Altschuler RA
[Ad] Endereço:Department of Biomedical Engineering, University of Michigan, Ann Arbor, 48109.
[Ti] Título:Persistence, distribution, and impact of distinctly segmented microparticles on cochlear health following in vivo infusion.
[So] Source:J Biomed Mater Res A;104(6):1510-22, 2016 Jun.
[Is] ISSN:1552-4965
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Delivery of pharmaceuticals to the cochleae of patients with auditory dysfunction could potentially have many benefits from enhancing auditory nerve survival to protecting remaining sensory cells and their neuronal connections. Treatment would require platforms to enable drug delivery directly to the cochlea and increase the potential efficacy of intervention. Cochlear implant recipients are a specific patient subset that could benefit from local drug delivery as more candidates have residual hearing; and since residual hearing directly contributes to post-implantation hearing outcomes, it requires protection from implant insertion-induced trauma. This study assessed the feasibility of utilizing microparticles for drug delivery into cochlear fluids, testing persistence, distribution, biocompatibility, and drug release characteristics. To allow for delivery of multiple therapeutics, particles were composed of two distinct compartments; one containing polylactide-co-glycolide (PLGA), and one composed of acetal-modified dextran and PLGA. Following in vivo infusion, image analysis revealed microparticle persistence in the cochlea for at least 7 days post-infusion, primarily in the first and second turns. The majority of subjects maintained or had only slight elevation in auditory brainstem response thresholds at 7 days post-infusion compared to pre-infusion baselines. There was only minor to limited loss of cochlear hair cells and negligible immune response based on CD45+ immunolabling. When Piribedil-loaded microparticles were infused, Piribedil was detectable within the cochlear fluids at 7 days post-infusion. These results indicate that segmented microparticles are relatively inert, can persist, release their contents, and be functionally and biologically compatible with cochlear function and therefore are promising vehicles for cochlear drug delivery. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1510-1522, 2016.
[Mh] Termos MeSH primário: Cóclea/fisiologia
Microesferas
Piribedil/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Contagem de Células
Morte Celular/efeitos dos fármacos
Cóclea/efeitos dos fármacos
Liberação Controlada de Fármacos
Potenciais Evocados Auditivos do Tronco Encefálico/efeitos dos fármacos
Cobaias
Células Ciliadas Auditivas/citologia
Células Ciliadas Auditivas/efeitos dos fármacos
Imuno-Histoquímica
Piribedil/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160204
[St] Status:MEDLINE
[do] DOI:10.1002/jbm.a.35675


  5 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26525631
[Au] Autor:Fedorova NV; Kulua TK; Gubanova ЕN
[Ad] Endereço:Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia; Center of Extrapyramidal Disorders, Moscow.
[Ti] Título:[The use of piribedil in early and late stages of Parkinson's disease].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;115(10):96-98, 2015.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:In this article, we present clinical cases at an early stage of Parkinson's disease with mild affective and cognitive disorders, and at a later stage with motor fluctuations and levodopa-induced dyskinesia. The efficacy of dopamine receptor agonists in treatment of Parkinson's disease in the early and late stages is illustrated by the example of piribedil.
[Mh] Termos MeSH primário: Antiparkinsonianos/uso terapêutico
Agonistas de Dopamina/uso terapêutico
Doença de Parkinson/tratamento farmacológico
Piribedil/uso terapêutico
[Mh] Termos MeSH secundário: Discinesia Induzida por Medicamentos/tratamento farmacológico
Discinesia Induzida por Medicamentos/etiologia
Feminino
Seres Humanos
Levodopa/efeitos adversos
Levodopa/uso terapêutico
Meia-Idade
Doença de Parkinson/psicologia
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Dopamine Agonists); 46627O600J (Levodopa); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151104
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro201511510196-98


  6 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26125261
[Au] Autor:Song JH; Zhou PY; Cao ZH; Ding ZG; Chen HX; Zhang GB
[Ad] Endereço:Department of Neurology, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China. zgb1969@126.com.
[Ti] Título:Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
[So] Source:Eur Rev Med Pharmacol Sci;19(11):2001-7, 2015.
[Is] ISSN:2284-0729
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Discuss the effect of rhythmic auditory stimulation with visual stimuli on motor and balance function in patients with Parkinson's disease (PD). PATIENTS AND METHODS: One hundred and sixteen patients with PD participated in this study. The control group used a routine drug treatment for eight weeks. The comprehensive treatment group used conventional drug treatment with sound rhythm metronome released as the rhythmical auditory stimulation, in accordance with the ground fixed ribbon rhythmic visual stimulation walking training for eight weeks. After four and eight weeks, the two groups of subjects took the walking parameters test, and used the disease Parkinson score scale to assess the damaged degree of motor function of PD patients. The Berg Balance Scale was used to evaluate the balance function of the PD patients. A six minute walk test was used to evaluate the walking motor function of the patients. RESULTS: The comparison between the groups suggests that after treatment of rhythmic auditory stimulation with visual stimulation group, the step size increased, frequency decreased, pace increased, and PD score scale part II decreased. As well, the PD score scale part III reduced, the six minute walking distance increased, and the Berg Balance Scale score increased significantly. There were significant differences compared with the control group after the treatment (p < 0.01). Comparison of time points suggests that after rhythmic auditory stimulation with visual stimulation group trained for eight weeks, the step size increased, frequency decreased, pace increased, and PD score scale part II were reduced. As well the PD score scale part III reduced, six minute walking distance increased, Berg Balance Scale increased. There were significant differences compared with the parameters of training for four weeks (p < 0.01). CONCLUSIONS: Rhythmic auditory stimulation with visual stimulation can improve motor and balance function of patients with PD.
[Mh] Termos MeSH primário: Estimulação Acústica
Doença de Parkinson/reabilitação
Periodicidade
Equilíbrio Postural
[Mh] Termos MeSH secundário: Idoso
Benserazida/uso terapêutico
Benzotiazóis/uso terapêutico
Catecóis/uso terapêutico
Relação Dose-Resposta a Droga
Combinação de Medicamentos
Feminino
Marcha
Seres Humanos
Levodopa/uso terapêutico
Masculino
Meia-Idade
Nitrilos/uso terapêutico
Doença de Parkinson/tratamento farmacológico
Doença de Parkinson/fisiopatologia
Piribedil/uso terapêutico
Caminhada
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Benzothiazoles); 0 (Catechols); 0 (Drug Combinations); 0 (Nitriles); 0 (benserazide, levodopa drug combination); 46627O600J (Levodopa); 4975G9NM6T (entacapone); 762OS3ZEJU (Benserazide); 83619PEU5T (pramipexole); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150701
[Lr] Data última revisão:
150701
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150701
[St] Status:MEDLINE


  7 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:25742580
[Au] Autor:Micheli FE; Giugni JC; Espinosa ME; Calvo DS; Raina GB
[Ad] Endereço:Unidad de Enfermedades y Trastornos de Movimiento de Parkinson, Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Buenos Aires, Argentina.
[Ti] Título:Piribedil and pathological gambling in six parkinsonian patients.
[So] Source:Arq Neuropsiquiatr;73(2):115-8, 2015 Feb.
[Is] ISSN:1678-4227
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Impulse control disorders (ICD) in Parkinson's disease (PD) have attracted increasing interest. They are characterized by the inability to control the impulse to perform an act that can be detrimental to them or to others. Although dopamine agonists (DA), as a group, have been associated with impulse control disorders (ICD), piribedil has rarely been reported to cause them. METHOD: Case reports of six parkinsonian patients on piribedil presenting pathological gambling (PG). RESULTS: All of the patients presented ICD associated with piribedil use. Two of them received this medication as first treatment and four of them who had developed ICDs secondary to other DA that reappeared with piribedil. CONCLUSION: Despite piribedil is commercially available in only a few countries, it should be considered in the differential diagnosis of PG in patients with PD.
[Mh] Termos MeSH primário: Antiparkinsonianos/efeitos adversos
Agonistas de Dopamina/efeitos adversos
Jogo de Azar/induzido quimicamente
Doença de Parkinson/tratamento farmacológico
Piribedil/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Doença de Parkinson/psicologia
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Dopamine Agonists); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:150306
[Lr] Data última revisão:
150306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150306
[St] Status:MEDLINE


  8 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26118093
[Au] Autor:Bachyns'ka NIu; Rozheliuk IF
[Ti] Título:[USAGE OF PRONORAN® FOR TREATMENT OF ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT].
[So] Source:Lik Sprava;(7-8):98-110, 2014 Jul-Aug.
[Is] ISSN:1019-5297
[Cp] País de publicação:Ukraine
[La] Idioma:ukr
[Ab] Resumo:Evaluated the effectiveness of Pronoran® for treatment of elderly patients with syndrome of mild cognitive impairment (MCI) with underlying dyscirculatory encephalopathy. The study involved 48 people: I (main) group--27 patients who in addition to basic therapy received Pronoran®, II (control) group--21 patients, received only basic therapy. We found that exposure to a 3-month treatment course for patients of the I (main) group showed significant improvement in terms of indicators characterizing orientation in space, short-term memory, counting ability, concentration, psychomotor pace, ability to learn. In addition, the treatment course was accompanied by improved emotional state, positive changes in the coefficients of the spectral power qEEG for patients. At the same time, the patients in the II (control) group didn't show significant changes in the studied parameters.
[Mh] Termos MeSH primário: Envelhecimento/psicologia
Encefalopatias/tratamento farmacológico
Transtornos Cognitivos/tratamento farmacológico
Agonistas de Dopamina/uso terapêutico
Piribedil/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Encefalopatias/complicações
Encefalopatias/psicologia
Transtornos Cognitivos/complicações
Transtornos Cognitivos/psicologia
Agonistas de Dopamina/administração & dosagem
Eletroencefalografia
Seres Humanos
Piribedil/administração & dosagem
Receptores de Dopamina D2/agonistas
Receptores de Dopamina D3/agonistas
Índice de Gravidade de Doença
[Pt] Tipo de publicação:CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DRD2 protein, human); 0 (Dopamine Agonists); 0 (Receptors, Dopamine D2); 0 (Receptors, Dopamine D3); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150630
[St] Status:MEDLINE


  9 / 418 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25782306
[Au] Autor:Il'nitskii AN; Proshchaev KI; Shvartsman GI; Bakhmutova IuV; Pozdniakova NM; Krivetskii VV; Varavina LIu
[Ti] Título:[The use of piribedil for the prevention of falls in elderly patients with metabolic syndrome].
[So] Source:Klin Med (Mosk);92(5):46-50, 2014.
[Is] ISSN:0023-2149
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Effects of pirebedil used to prevent falls in elderly patients with metabolic syndrome are discussed. A prospective controlled study showed that therapy with pirebedil significantly decreases the frequency of falls, reduces severity of pro-inflammatory and pro-oxidative activities, improves cognitive abilities. Prevention of falls by virtue of improved cognitive abilities is a new clinical effect of pirebedil and gives reason to recommend it for the treatment of geriatric patients with metabolic syndrome.
[Mh] Termos MeSH primário: Acidentes por Quedas/prevenção & controle
Encefalopatias Metabólicas
Diabetes Mellitus Tipo 2
Competência Mental
Piribedil
[Mh] Termos MeSH secundário: Idoso
Encefalopatias Metabólicas/tratamento farmacológico
Encefalopatias Metabólicas/etiologia
Encefalopatias Metabólicas/fisiopatologia
Encefalopatias Metabólicas/psicologia
Diabetes Mellitus Tipo 2/complicações
Diabetes Mellitus Tipo 2/metabolismo
Agonistas de Dopamina/administração & dosagem
Agonistas de Dopamina/farmacocinética
Feminino
Avaliação Geriátrica/métodos
Seres Humanos
Masculino
Meia-Idade
Nootrópicos/administração & dosagem
Nootrópicos/farmacocinética
Piribedil/administração & dosagem
Piribedil/farmacocinética
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Agonists); 0 (Nootropic Agents); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:150318
[Lr] Data última revisão:
150318
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150319
[St] Status:MEDLINE


  10 / 418 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24992083
[Au] Autor:Eggert K; Öhlwein C; Kassubek J; Wolz M; Kupsch A; Ceballos-Baumann A; Ehret R; Polzer U; Klostermann F; Schwarz J; Fuchs G; Jost W; Albert A; Haag A; Hermsen A; Lohmüller K; Kuhn K; Wangemann M; Oertel WH; In Cooperation With the German Competence Network on Parkinson's Disease
[Ad] Endereço:*Department of Neurology, Philipps-University of Marburg, Marburg, Germany; †Gera, Germany; ‡Department of Neurology, University of Ulm, Ulm, Germany; §Department of Neurology, Elblandklinikum, Meissen, Germany; ∥Department of Neurology & Stereotactic Neurosurgery, Otto-von-Guericke-University, Magdeburg, Germany; ¶Department of Neurology, Schön Klinik München Schwabing and Technische Universität, München, Germany; #Neuro-Zentrum Steglitz, Berlin, Germany; ** Department of Neurology, Asklepios Fachklinikum, Stadtroda, Germany; ††Department of Neurology, CBF-Charité University Medicine, Berlin, Germany; ‡‡Department of Neurology, Klinik Haag, Haag Germany; §§Parkinson Klinik, Wolfach, Germany; and ∥∥Desitin Arzneimittel GmbH, Hamburg, Germany.
[Ti] Título:Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
[So] Source:Clin Neuropharmacol;37(4):116-22, 2014 Jul-Aug.
[Is] ISSN:1537-162X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to investigate the effects of piribedil on vigilance and cognitive performance in patients with Parkinson disease experiencing excessive daytime sleepiness on pramipexole or ropinirole. METHODS: In this 11-week randomized, active-controlled, rater-blinded phase III study, eligible patients were randomly assigned to either receive piribedil or to continue on pramipexole or ropinirole. The primary outcome was the median reaction times during the second 15 minutes of the subtest "vigilance" of the Test battery for Attention Performances (TAP). Secondary outcomes included the Epworth Sleepiness Scale, Unified Parkinson's Disease Rating Scale, neuropsychological testing, and items of the Clinical Global Impression. RESULTS: Forty-four patients received piribedil; 36 continued on either pramipexole or ropinirole. There was no difference in the primary end point reaction time of the TAP subtest vigilance between piribedil and the comparator (996 vs 954 milliseconds, P = 0.68). Piribedil reduced daytime sleepiness with lower Epworth Sleepiness Scale scores at the end of treatment compared with the comparator (-4 vs -2 points; P = 0.01). The median Unified Parkinson's Disease Rating Scale III score at the end of treatment was comparable between the 2 groups. Neuropsychological tests revealed no significant between-treatment differences. A higher therapeutic effect and global improvement were shown by the Clinical Global Impression of piribedil-treated patients. CONCLUSIONS: This study shows that switching from pramipexole or ropinirole to piribedil has no effect on the reaction time of the TAP subtest vigilance but upholds the same therapeutic motor effect and reduces daytime sleepiness to a clinically relevant degree in patients with excessive daytime sleepiness.
[Mh] Termos MeSH primário: Antiparkinsonianos/uso terapêutico
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Transtorno do Deficit de Atenção com Hiperatividade/etiologia
Distúrbios do Sono por Sonolência Excessiva/tratamento farmacológico
Doença de Parkinson/complicações
Doença de Parkinson/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Benzotiazóis
Método Duplo-Cego
Feminino
Seres Humanos
Indóis
Masculino
Meia-Idade
Testes Neuropsicológicos
Piribedil
Tempo de Reação/efeitos dos fármacos
Índice de Gravidade de Doença
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Benzothiazoles); 0 (Indoles); 030PYR8953 (ropinirole); 83619PEU5T (pramipexole); DO22K1PRDJ (Piribedil)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:140716
[Lr] Data última revisão:
140716
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140704
[St] Status:MEDLINE
[do] DOI:10.1097/WNF.0000000000000041



página 1 de 42 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde